News
Leading Provider of Innovative Scientific and Technology Services Welcomes Mark Skeen, MD as Senior Medical Scientist
VeraSci recently welcomed Mark Skeen, MD as Senior Medical Scientist. In this role Dr. Skeen will provide disease state expertise for a broad range of neurologic diseases as well as the perspective of the clinician conducting clinical trials. As part of his role at...
read moreSignificant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform
Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform Integrating Clinical, Cognitive and Functional Assessments onto one device. Durham, NC—December 6, 2018—VeraSci, a global clinical technology and research services company,...
read moreNeuroCog Trials is now VeraSci
Durham, NC—October 12, 2018— NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery....
read moreLEADING ALZHEIMER’S DISEASE SCIENTIST JOINS NEUROCOG TRIALS
DURHAM, NC, July 9, 2018– Specializing in Alzheimer’s Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials...
read moreNeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease
Innovative technology answers the call for improved functional capacity measurements in cognitive disorders Durham, North Carolina, October 30, 2017 -- NeuroCog Trials, Inc. (NCT), the premier global cognition and clinical assessment consulting and technology company,...
read moreFORMER DIRECTOR GENERAL OF THE ITALIAN MEDICINES AGENCY (AIFA) DR. LUCA PANI JOINS NEUROCOG TRIALS
Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and...
read moreNCT Linguistics Sponsors Triangle Biotech Tuesday – Press Release
DURHAM, NORTH CAROLINA, May 19, 2017 NCT Linguistics, a leading global provider of translation, interpretation, and training services, was honored to sponsor Triangle Biotech Tuesday in Research Triangle Park on Tuesday, May 9, 2017. Triangle Biotech Tuesday is a...
read moreNCT Linguistics and NeuroCog Trials Expand Workforce, Office Space At Durham Headquarters
DURHAM, NC, Nov. 30, 2016 — NeuroCog Trials, the leading cognitive services provider for the clinical trials industry, today announced that it is significantly expanding its presence at its headquarters in Durham. Construction is currently underway to give NeuroCog...
read moreNCT Linguistics and Percept Research Announce Partnership – Press Release
NCT Linguistics becomes the exclusive provider of translation services for Percept Research DURHAM, NORTH CAROLINA, October 10, 2016 – NCT Linguistics, the boutique language solutions provider, today announced that it has signed an exclusive agreement with Percept...
read moreCognitive Dysfunction as a Treatment Target in Depression
NeuroCog Trials welcomes the outcome of the FDA Psychopharmacologic Drug Advisory Committee meeting that cognitive dysfunction in Major Depressive Disorder (MDD) represents an appropriate drug development target. The issue was discussed at the meeting on February 3rd...
read more